UBS Group’s CELATOR PHARMACEUTICALS INC. COMMON STOCK CPXX Stock Holding History

UBS Group’s Portfolio CPXX Stock Details CPXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-600	Closed	-$18K	–	8325
2016 Q2	$18K	Buy	600 +247	+70%	+$5.01K	﹤0.01%	6405
2016 Q1	$4K	Buy	+353	New	+$1.16K	﹤0.01%	7149
2015 Q4	–	Sell	-500	Closed	-$1K	–	8809
2015 Q3	$1K	Sell	500 -2,134	-81%	-$4.74K	﹤0.01%	8308
2015 Q2	$6K	Buy	+2,634	New	+$5.97K	﹤0.01%	7831

UBS Group's CPXX Position: Q3 2016 in Review

UBS Group sold out of CELATOR PHARMACEUTICALS INC. COMMON STOCK (CPXX) in Q3 2016, closing a stake of 600 shares — an estimated $18K sold.

UBS Group first reported a position in CPXX in Q2 2015 and held it in 4 quarters. The position peaked at $18K in Q2 2016. 0 funds tracked by Wall St. Rank hold CPXX as of Q3 2016.

UBS Group reported no remaining CELATOR PHARMACEUTICALS INC. COMMON STOCK position as of Q3 2016 after selling out during the quarter.
UBS Group sold 600 CELATOR PHARMACEUTICALS INC. COMMON STOCK shares in Q3 2016, an estimated $18K.
UBS Group first reported a position in CELATOR PHARMACEUTICALS INC. COMMON STOCK in Q2 2015 and held it in 4 quarters.
UBS Group's CELATOR PHARMACEUTICALS INC. COMMON STOCK position peaked at $18K in Q2 2016.
0 funds tracked by Wall St. Rank held CELATOR PHARMACEUTICALS INC. COMMON STOCK as of Q3 2016.

Based on UBS Group's 13F filing for Q3 2016, filed 14 Nov 2016.